AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer10 Feb 2025
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions
Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Nippon Shinyaku and Atsena Therapeutics Enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
Ascend Advanced Therapies Partners with EW Healthcare Partners to Expand United States Capacity and Capabilities
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
Ascend Advanced Therapies: Continued Investment in Technology & Flexible Capacity Includes New Fill/Finish Capabilities
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Abingworth appoints Robert DeBenedetto as Managing Director – Clinical Co-Development
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Pathalys Pharma Secures $105 Million Series B Financing
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Reneo Pharmaceuticals And OnKure Announce Proposed Merger
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA For DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-In-Class Oral MRGPR Antagonists
Ascend acquires GMP manufacturing capacity in Alachua, Florida from Beacon Therapeutics
Clinical Collaboration Agreement Established between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System
Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee between Launch Therapeutics and Gilead Sciences
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
Iambic Therapeutics Marks a Key Milestone in Advancing Cancer Treatment: IND Submission for IAM1363, a Selective, Brain-Penetrant HER2 Inhibitor
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Q32 Bio and Homology Medicines Announce Merger Agreement
Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen
Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
Soleno Therapeutics Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting
Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases
Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors
Gene & cell therapy manufacturing specialist Ascend launches with over $130M of funding as expert teams merge
Vaxcyte Announces Pricing of $500 Million Public Offering
Vaxcyte Reports Positive Data from Ph 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Ph 1/2 and Ph 2 Studies
Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD
Wugen Announces CEO Transition
Spruce Biosciences Announces $53.6 Million Private Placement Financing
Harvey Schwartz Named CEO of Carlyle and Member of the Board
Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies
Avillion announces US approval of AstraZeneca’s Airsupra (PT027) as new rescue treatment for Asthma
Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
Abingworth appoints experienced life sciences investor Joy Ghosh, PhD as Managing Director
Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Escient Pharmaceuticals Announces $120 Million Series C Financing
Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an ‘off-the shelf’ Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer
PT027 recommended by FDA Advisory Committee as new rescue treatment for asthma
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Anjarium Biosciences Appoints Gaurav Shah as Chairperson and Douglas Fambrough as Non-executive Director
Vaxcyte Expands Executive Leadership Team with Key Appointments
Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
Launch Therapeutics partners with Opthea to advance OPT-302, a promising therapy for wet AMD
Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
Carlyle Completes Acquisition of Abingworth and Announces Go-forward Leadership Team; Acquisition Expands Global Healthcare Franchise with Leading Life Sciences Investment Expertise
GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®
Anjarium Biosciences appoints experienced industry executives Samantha Vieira as Chief Operating Officer and Nate Massari as Chief Business Officer
Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors
GSK completes acquisition of Sierra Oncology
Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile
Anjarium Biosciences appoints Stephen Yoo, MD as Chief Executive Officer
Nouscom Announces Positive Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR / MSI-H Solid Tumors, at ASCO 2022
US FDA ACCEPTS NEW DRUG APPLICATION FILED BY AVILLION FOR ASTRAZENECA’S PT027 FOR THE AS-NEEDED TREATMENT OR PREVENTION OF SYMPTOMS IN ASTHMA PATIENTS
Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform
Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia
AVILLION ANNOUNCES PUBLICATION OF POSITIVE FULL RESULTS FROM MANDALA PHASE III TRIAL OF ASTRAZENECA’S PT027 IN ASTHMA PATIENTS IN THE NEW ENGLAND JOURNAL OF MEDICINE
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
HilleVax announces pricing of upsized Initial Public Offering
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors
We are delighted to announce that Abingworth LLP will become part of The Carlyle Group
Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI
Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
Abingworth notes the passing of David Leathers, a former Director and Special Partner
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis
Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets
Second Abingworth gamma delta T cell company, Adaptate Biotherapeutics, to be acquired by Takeda
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
SPRUCE BIOSCIENCES APPOINTS JAVIER SZWARCBERG, M.D., MPH AS CHIEF EXECUTIVE OFFICER
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
Novo Nordisk to Acquire Dicerna
Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001
Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy
Abingworth appoints Jayson Punwani as Partner
Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen
Abingworth portfolio company GammaDelta Therapeutics to be acquired by Takeda
Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
NuCana receives Fast Track Designation from the FDA for Acelarin (NUC-1031) for the Treatment of Biliary Tract Cancer
Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members
Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies
Nouscom announces initial results from Phase 1 trial for NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine, in MSI-H solid tumors
GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of GDX012 for the Treatment of Acute Myeloid Leukaemia
Abingworth strengthens investment team with new appointments in the US and UK
Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca’s PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies | eFFECTOR Therapeutics
Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer
NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer
Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer
Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors
Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders
CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth
Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials, co-led by Abingworth
Vera Therapeutics welcomes new CFO Sean Grant
Scorpion Therapeutics announces new CEO Axel Hoos, M.D., PhD
Delighted to share the appointment of Adam Cutler as CFO at Q32 Bio
Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1
Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection
Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease
We are pleased to share Atsena Therapeutics has appointed Kenji Fujita, MD, as Chief Medical Officer
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
Sierra Oncology Welcomes Two New Independent Directors to its Board
Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. announce merger agreement to create publicly listed, next-generation oncology company developing new class of cancer therapies
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Vera Therapeutics Announces Pricing of Initial Public Offering
Congratulations Brian Bock, newly appointed CFO of Exicure
Abingworth raises $582 million for new Clinical Co-Development Fund – ACCD 2
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation
Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
Adaptate Biotherapeutics raises $18 Million in series A2 funding
Congratulations Greg and team on the successful IPO of Reneo Pharma on Nasdaq (ticker: RPHM)
Delighted to share Reneo Pharmaceuticals has appointed Vineet R. Jindal as Chief Financial Officer
Pleased to announce Reneo Pharmaceuticals has appointed Eric Dube, Ph.D. to its Board of Directors
Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy
Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate
Exicure announces appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to its Board of Directors
We are delighted that Q32 Bio has appointed Dr. Jason Campagna as Chief Medical Officer
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement
Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
Abingworth raises $465m for new life sciences fund Abingworth Bioventures 8
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
We are pleased to announce Vera Therapeutics has launched with an $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
Congratulations Gary Glick, CEO and the Scorpion Therapeutics team on an oversubscribed $162 million Series B financing
Congratulations Mark Iwicki, newly appointed Chairman of portfolio co. Q32 Bio
We are delighted that portfolio co. NuCana have appointed Andrew Kay as Chairman
Abingworth promotes Bali Muralidhar to Managing Partner
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
Congratulations to the Reneo team on their $95 Million Series B Financing, Co-led by Novo Ventures and Abingworth
Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID Undergoing Hematopoietic Cell Transplantation
Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting
Congratulations to Michael Broxson and team as Q32 Bio close a $60 Million Series B Financing, Advancing Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
Positive results from Avillion's Phase 2 trial of sonelokinab (M1095) in chronic psoriasis to be presented today in Late-Breaking News Session at EADV 2020 Virtual
SFJ Pharmaceuticals® partner, Apellis, enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications outside the U.S.
Scorpion Therapeutics debuts with $108M to 'put the sting in cancer'
Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer
NuCana expands its Board of Directors with the Appointment of Abingworth Partner, Bali Muralidhar
Congratulations Richard, Samir and the team for the successful IPO of Spruce Biosciences on NASDAQ (Ticker: SPRB).
We are extremely pleased to see Professor Charpentier, co-founder of CRISPR Therapeutics, become a Nobel Laureate
Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent for Patients with Myelodysplastic Syndromes/Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM
Tizona Appoints Christine O’Brien as Chief Executive Officer
AVILLION ANNOUNCES POSITIVE TOP-LINE RESULTS OF PHASE 2 TRIAL OF SONELOKINAB (M1095)
Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues
Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen
Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability
Gilead Sciences Secures Exclusive Option to Aquire Tizona Therapeutics for $300 Million
Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study
Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vaxcyte Announces Pricing of Upsized Initial Public Offering
Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
Spruce Biosciences Announces Launch of CAHstudy.com to Initiate Screening of Patients for CAH Clinical Program
Spruce Biosciences Strengthens Leadership Team with Appointments of Samir Gharib as CFO and Dasharatha Reddy as VP of Pharmaceutical Development and Manufacturing
SutroVax Appoints Andrew Guggenhime as Chief Financial Officer and Chief Business Officer
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
eFFECTOR’S Zotatifin demonstrates in vitro Anti-SARS-COV-2 activity in independent international study reported in Peer-reviewed journal Nature
Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections with Limited Treatment Options
FirstWave Bio to Initiate Phase 2a/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
Nouscom Strengthens its Management Team
Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth
Verona Pharma Announces Senior Management Changes
eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types
Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock
Median Technologies announces the signing of a € 35 million finance contract with the European Investment Bank (EIB)
Venatorx Pharmaceuticals Joins the Alliance for Biosecurity
Jasper Therapeutics Launches with $35 Million Series A Financing to Develop and Commercialize Innovative Conditioning Agents and Therapies to Transform Curative Hematopoietic Cell Transplants
IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer
Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors
CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea
Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders
Abingworth appoints Neil Cooper as Chief Financial Officer
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants
Phathom Pharmaceuticals Announces Pricing of Initial Public Offering
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due
Avillion Appoints Dr Anders Gersel Pedersen, M.D., Ph.D. as Board Member
VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
Exicure Appoints Dr. Bali Muralidhar of Abingworth to its Board of Directors
Exicure Announces Uplisting to Nasdaq and Closing of $63 Million Offering of Common Stock
Glaukos and Avedro Announce Definitive Acquisition Agreement
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly
HHS, DoD, VenatoRx Pharmaceuticals to co-develop novel antibiotic to treat drug-resistant infections
Personalis Prices Initial Public Offering of Common Stock
Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics
Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
IND for NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals
Lloyd Diamond will serve as Chief Executive Officer of Pixium Vision
Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval
VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019
Abingworth appoints Bali Muralidhar as Partner
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
Avedro Announces Pricing of Initial Public Offering
IFM Therapeutics Launches New Subsidiary, IFM Due, to Advance cGAS/STING Antagonists for Serious Inflammatory and Autoimmune Diseases
GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)
Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
Beckman Coulter Life Sciences Acquires Labcyte To Expand Laboratory Automation Business
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
Pixium Vision announces its wireless PRIMA chip successfully met the interim study endpoints for dry Age-related Macular Degeneration
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease
Gynesonics Announces $75 Million Financing
AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in Cancer
Soleno Therapeutics Announces $16.5 Million Private Placement
Virion Biotherapeutics Appoints Edwin Moses as Chairman of the Board and Guido Dietrich as Head of Manufacturing
Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences
Sinclair Pharma Announces Acquisition of the Company by Huadong Medicine Co Ltd
Virion Biotherapeutics Demonstrates Preclinical Proof-of-Concept for First Therapeutic Interfering Particle Candidate in Respiratory Virus Infections
Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with Bradanicline
Abingworth appoints Jackie Grant as Principal
GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
Personalis Receives New Order from the VA’s Million Veteran Program – Total Contracted Now Almost 80,000 Whole Human Genomes
Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)
FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne
US FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
VenatoRx Pharmaceuticals and Everest Medicines II Limited Announce Exclusive License Agreement for cefepime/VNRX-5133
Abingworth appoints Brian Gallagher, Jr as Partner
Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO
Gynesonics Receives FDA Clearance to Market Sonata® System
FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases
Abingworth raises $315m for ABV VII - 12th life sciences fund
IFM Therapeutics, LLC Appoints World-Renowned Physicians and Researchers to Clinical Advisory Board
SutroVax Announces $85M Series C Financing led by TPG Growth
Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
Sientra Announces Pricing of Upsized Public Offering of Common Stock
Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growth
Attenua Raises $35M in Series A Financing to Advance Therapy for Chronic Cough
Lombard Medical Acquired by MicroPort Scientific Corporation in a Restructuring Transaction
MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy
Sientra Receives FDA Approval of PMA Supplement
Alexion to Acquire Wilson Therapeutics
Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)
IFM Co-Founder Dr. Eicke Latz Receives 2018 Leibniz Prize
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
Avillion Signs Co-Development Agreement with Pearl Therapeutics Inc. (part of AstraZeneca) to Conduct Clinical Development of PT027 in Asthma
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients
Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®
MSD and Viralytics Announce Acquisition Agreement, Expanding MSD’s Leading Immuno-Oncology Pipeline
First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease
Labcyte Acoustic Liquid Handlers Named Top Product in Lab Automation Conference Awards
Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-StageBreast Cancer Program to Its Oncology Pipeline
Pixium Vision completes World’s First Successful Activation in Human of PRIMA Bionic Vision System
Paratek Announces Pricing of Public Offering of Common Stock
GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa
Gynesonics announces results from pivotal IDE trial for incision free treatment for Uterine Fibroids
CRISPR Therapeutics Announces Appointment of Dr Rodger Novak as Chairman of the Board
Avillion announces US approval of Pfizer’s BOSULIF®
WTX101 granted Fast Track designation by the U.S. FDA for the treatment of Wilson Disease
Wilson Therapeutics has completed a directed share issue of approximately SEK 244 million
CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia - Phase 1/2 trial in β-thalassemia expected to begin in 2018
Personalis Awarded New Contract with the US Department of Veterans Affairs to Provide Clinical Cancer Genomic Testing and Analysis for the Precision Oncology Program
​NousCom’s Neoantigen-based Vaccine Synergizes with NKTR-214 to Cure Established Tumors in Preclinical Model
Personalis Wins New Contract to Sequence >34,000 Whole Human Genomes for the VA’s Million Veteran Program
NousCom Raises €42 Million Series B Financing
Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease
VirionHealth Raises Series A Funding from Abingworth
CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer
Promising preliminary long-term data from WTX101 Phase 2 extension study to be presented at AASLD Annual Meeting
Pixium Vision announces H1 2017 financial results and provides an update on its activities
Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly
Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)
BOSULIF 1L Regulatory Submissions Acceptance
Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)
Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity
Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
VenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite back industry‐leading antibiotics developer
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors
Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe
Proteon Therapeutics Announces $22.0 Million Private Placement
eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer
Sientra to Acquire Miramar Labs®
Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer
Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations
GammaDelta Therapeutics expands management team led by Paolo Paoletti as CEO
Avedro Announces $42 Million in Funding to Support Commercial Expansion and Pipeline Development
Verona Pharma Announces Pricing of Global Offerin
Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting
Lombard Medical Appoints New CEO
Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial
Dynex Technologies Acquired By Telegraph Hill Partners
Avillion signs Clinical Co-Development Agreement with Merck to Advance Anti IL-17 A/F Nanobody® in Psoriasis
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554
SutroVax Announces Closing of $64M via Series B Financing
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
Verona Pharma Commences further RPL554 Phase 2a Clinical Trial
GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
Lombard Medical and MicroPort Scientific Corporation Announce Strategic Partnership and Investment Agreement
Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease
MEDIAN Technologies announces a reserved share capital increase to FURUI of €19.6 Million at a €13 per share price
Casebia Therapeutics Press Release: Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer
IFM Therapeutics Establishes German Subsidiary and Research Site
Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors
http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2212807
GammaDelta Therapeutics Raises Seed Funding from Abingworth
Avedro Appoints Dr. Reza Zadno As Chief Executive Officer
Pixium Vision announces CE market approval of IRIS®II, its first bionic vision system
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
Verona Pharma - Proposed Placing to raise c. £44.7 million and Notice of General Meeting
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated
Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa™
GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
Final price in Wilson Therapeutics’ initial public offering set at SEK 49 per share – trading on Nasdaq Stockholm commences today
Stryker acquires Stanmore Implants Worldwide Limited
Wilson Therapeutics announces initial public offering on Nasdaq Stockholm
Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa™ New Drug Application
Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking
Epigenomics receives FDA approval for Epi proColon®
Meridian Bioscience Acquires Magellan Diagnostics, Inc.
Senseonics to Ring Opening Bell at the New York Stock Exchange
CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise
Tizona Therapeutics Inc Completes $43 Million Series B Financing
Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy
eFFECTOR Therapeutics Increases its Series B Financing Round to $56M
Sientra Announces Return of All Products to U.S. Market
Abingworth raises $105m for First Dedicated Clinical Co-Development Fund
eFFECTOR Therapeutics Raises $40 Million - Series B Financing
Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases
CRISPR Therapeutics Appoints Tony Coles to its Board of Directors
Senseonics Holdings, Inc. and ASN Technologies, Inc. Announce Closing of Merger
Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences
Kesios Therapeutics Raises £19 Million In Series A Financing
Gynesonics Completes $46 million Equity Financing
Sientra Appoints Jeffrey Nugent Chairman and Chief Executive Officer
Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases
Wilson Therapeutics Appoints Andrew Kay as Chairman
Abingworth appoints Dr Shelley Chu
Sientra Sends Letter to Plastic Surgeons Regarding Silimed-Manufactured Products
Sientra Issues Statement Regarding Recent ANVISA Announcement
Dear Doctor Letter
Sientra® Prices Follow-On Public Offering of Common Stock
GenSight Biologics Closes $36 Million Series B Preferred Stock Financing
SutroVax raises $22 million in Series A
Gynesonics Raises $43 million in Equity Financing
Abingworth appoints Tim Haines and Kurt von Emster as joint Managing Partners
MEDIAN Technologies announces a private placement of €19.8 Million at a €12 share price
CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients
Chiasma Announces Mark Leuchtenberger as Chief Executive Officer
Quest Diagnostics to enhance diagnosis of Pediatric Neurological Disorders with exclusive whole exome sequencing from Personalis
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million
Chiasma Announces Completion of $70 Million Series E Financing
U.S. FDA approves anticancer agent LENVIMA™ (Lenvatinib Mesylate) as treatment for Radioactive Iodine-Refracory Differentiated Thyroid Cancer
Gynesonics Announces Another Peer-Reviewed Publication and Presentation of Significant International Clinical Experience With Vizablate Technology for Symptomatic Uterine Fibroids
Abingworth appoints Kurt von Emster as a Partner In Menlo Park
BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa’s Outstanding Stock
Sientra® Announces Closing of Initial Public Offering
Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals
ABILITY Network to acquire MD-Online Inc
Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance
Abingworth Promotes Ken Haas and Vin Miles to Partners
Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement
Paratek appoints Michael Bigham as Chairman and CEO and promotes Evan Loh to President and CMO
Pixium Vision raises €34.5 million (US$ 46.7 million) in successful IPO on Euronext Paris, after full exercise of the extension clause
Avillion elects Ulf Wiinberg, CEO of Lundbeck, as Chairman of its Board of Directors
Senseonics Raises $20 Million; Brings in New VP of Sales and Marketing
Lenvatinib Phase III Results Show Significant Improvement in Progression-Free Survival in Patients with Radioiodine-refractory Differentiated Thyroid Cancer
Proteon Therapeutics Announces $45 Million of Series D Financing
Avillion Announces Royalty Pharma Investment
Gynesonics Names Christopher M. Owens President, Chief Executive Officer
Wilson Therapeutics Secures $40 Million Private Financing to Advance Late Stage Development Program for Wilson's Disease
Pixium Vision appoints Khalid Ishaque as Chief Executive Officer
Abingworth raises £225m ($375m) in its tenth
Avillion appoints Dr Allison Jeynes-Ellis as Chief Executive Officer
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Ablynx Announces Worldwide Cancer Immunotherapy Discovery Collaboration and Licensing Agreement with Merck
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia
Supernus Announces FDA Approval of Its Partner's Product, Orenitram(TM)
Pixium Vision raises €15 million led by Sofinnova Partners
Cytos Biotechnology Ltd: Rights offering oversubscribed - CHF 24.3 million raised
Personalis Closes $22M Series B Financing
Ablynx and Abbvie Sign Global License Agreement for Anti-IL-6R Nanobody, ALX-0061, to Treat Inflammatory Diseases
Personalis Establishes UK Subsidiary and Appoints Mark Dronsfield as Director of European Sales
Supernus Launches Trokendi XR™ in the United States
Response Genetics, Inc. Acquires Proprietary FDA-Cleared and Medicare-Reimbursed Test and All Associated Assets for Difficult to Diagnose Solid Tumors